Diaceutics PLC (AIM:DXRX)
London · Delayed Price · Currency is GBP · Price in GBX 193.00
0.00 (0.00%)
Sep 25, 2026, 4:41 PM GMT
Diaceutics Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 41.33 | 38.44 | 32.16 | 23.7 | 19.5 | 13.94 | |
Revenue Growth | 20.14% | 19.53% | 35.69% | 21.51% | 39.88% | 9.82% |
Cost of Revenue | 7.08 | 6.96 | 3.89 | 3.99 | 2.76 | 1.71 |
Gross Profit | 34.25 | 31.48 | 28.27 | 19.71 | 16.74 | 12.23 |
Selling, General & Admin | 35.2 | 31.69 | 30.74 | 22.78 | 16.28 | 11.88 |
Other Operating Expenses | -0.15 | -0.26 | -0.02 | -0.06 | -0.11 | -0.2 |
Operating Expenses | 35.05 | 31.44 | 30.73 | 22.72 | 16.17 | 11.68 |
Operating Income | -0.79 | 0.04 | -2.46 | -3.02 | 0.58 | 0.55 |
Interest Expense | -0.06 | -0.06 | -0.05 | -0.07 | -0.12 | -0.09 |
Interest & Investment Income | 0.2 | 0.32 | 0.6 | 0.65 | 0.11 | - |
Other Non Operating Income (Expenses) | - | - | - | - | -0 | - |
EBT Excluding Unusual Items | -0.65 | 0.3 | -1.91 | -2.44 | 0.56 | 0.46 |
Pretax Income | -0.65 | 0.3 | -1.91 | -2.44 | 0.56 | 0.46 |
Income Tax Expense | -0.38 | 0.21 | -0.21 | -0.69 | -0.16 | -0.1 |
Net Income | -0.27 | 0.1 | -1.7 | -1.75 | 0.72 | 0.56 |
Net Income to Common | -0.27 | 0.1 | -1.7 | -1.75 | 0.72 | 0.56 |
Net Income Growth | - | - | - | - | 29.05% | 113.31% |
Shares Outstanding (Basic) | 85 | 85 | 84 | 84 | 84 | 84 |
Shares Outstanding (Diluted) | 85 | 85 | 84 | 84 | 86 | 85 |
Shares Change | 0.18% | 0.80% | 0.27% | -2.16% | 1.35% | 9.14% |
EPS (Basic) | -0.00 | 0.00 | -0.02 | -0.02 | 0.01 | 0.01 |
EPS (Diluted) | -0.00 | 0.00 | -0.02 | -0.02 | 0.01 | 0.01 |
EPS Growth | - | - | - | - | 27.29% | 94.55% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 3.89 | 1.11 | 0.55 | 1.19 | 4.91 | 0.01 |
Free Cash Flow Per Share | 0.05 | 0.01 | 0.01 | 0.01 | 0.06 | - |
Gross Margin | 82.88% | 81.90% | 87.91% | 83.15% | 85.83% | 87.73% |
Operating Margin | -1.92% | 0.11% | -7.63% | -12.73% | 2.95% | 3.94% |
Profit Margin | -0.66% | 0.25% | -5.30% | -7.37% | 3.71% | 4.02% |
Free Cash Flow Margin | 9.40% | 2.88% | 1.71% | 5.00% | 25.17% | 0.04% |
EBITDA | 3.86 | 4.09 | 0.55 | 0.1 | 2.08 | 1.52 |
EBITDA Margin | 9.34% | 10.63% | 1.72% | 0.43% | 10.64% | 10.88% |
D&A For EBITDA | 4.65 | 4.04 | 3.01 | 3.12 | 1.5 | 0.97 |
EBIT | -0.79 | 0.04 | -2.46 | -3.02 | 0.58 | 0.55 |
EBIT Margin | -1.92% | 0.11% | -7.63% | -12.73% | 2.95% | 3.94% |
Effective Tax Rate | - | 67.88% | - | - | - | - |